Literature DB >> 6403103

Factors related to first dose hypotensive effect of captopril: prediction and treatment.

G P Hodsman, C G Isles, G D Murray, T P Usherwood, D J Webb, J I Robertson.   

Abstract

The blood pressure response to the first dose of captopril (6.25 mg, 12.5 mg, or 25 mg) was measured in 65 treated, severely hypertensive patients. Mean supine blood pressure was 187/108 mm Hg immediately before captopril was given. Twenty one patients experienced a fall in supine systolic pressure greater than 50 mm Hg, including five whose pressure fell more than 100 mm Hg and two whose pressure fell more than 150 mm Hg. Six patients developed symptoms of acute hypotension, including dizziness, stupor, dysphasia, and hemiparesis. Percentage reductions in blood pressure were greatest in those with secondary hypertension (p less than 0.05), high pretreatment blood pressure (p less than 0.05), and high concentrations of plasma renin and angiotensin II (p less than 0.01). No significant correlation was found between fall in blood pressure and serum sodium concentration, age, renal function, and the dose of captopril given. A severe first dose effect cannot be consistently predicted in individual patients who have received other antihypertensive drugs for severe hypertension. Such patients should have close medical supervision for at least three hours after the first dose of captopril.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6403103      PMCID: PMC1547159          DOI: 10.1136/bmj.286.6368.832

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  17 in total

1.  Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients.

Authors:  D B Case; S A Atlas; J H Laragh; J E Sealey; P A Sullivan; D N McKinstry
Journal:  Prog Cardiovasc Dis       Date:  1978 Nov-Dec       Impact factor: 8.194

2.  Calibration and evaluation of a system of total body in vivo activation analysis using 14 MeV neutrons.

Authors:  E D Williams; K Boddy; I Harvey; J K Haywood
Journal:  Phys Med Biol       Date:  1978-05       Impact factor: 3.609

3.  Estimation of angiotensin II concentration in human plasma by radioimmunoassay. Some applications to physiological and clinical states.

Authors:  G Düsterdieck; G McElwee
Journal:  Eur J Clin Invest       Date:  1971-11       Impact factor: 4.686

4.  Renin relationships in congestive cardiac failure, treated and untreated.

Authors:  J J Brown; D L Davies; V W Johnson; A F Lever; J I Robertson
Journal:  Am Heart J       Date:  1970-09       Impact factor: 4.749

5.  Captopril compared with other antirenin system agents in hypertensive patients: its triphasic effects on blood pressure and its use to identify and treat the renin factor.

Authors:  J H Laragh; D B Case; S A Atlas; J E Sealey
Journal:  Hypertension       Date:  1980 Jul-Aug       Impact factor: 10.190

6.  The effect of captopril on blood pressure and angiotensins I, II and III in sodium-depleted dogs: problems associated with the measurement of angiotensin II after inhibition of converting enzyme.

Authors:  J J Morton; M Tree; J Casals-Stenzel
Journal:  Clin Sci (Lond)       Date:  1980-06       Impact factor: 6.124

7.  A microassay for active and total renin concentration in human plasma based on antibody trapping.

Authors:  J A Millar; B J Leckie; J J Morton; J Jordan; M Tree
Journal:  Clin Chim Acta       Date:  1980-02-14       Impact factor: 3.786

8.  Evidence that the acute hypotensive effect of captopril in dogs is not wholly explained by a reduction of plasma angiotensin II and its direct vasoconstrictor effect.

Authors:  M Tree; J J Morton
Journal:  Clin Sci (Lond)       Date:  1980-12       Impact factor: 6.124

9.  Acute changes in blood pressure and vasoactive hormones after captopril in hypertensive patients.

Authors:  B P McGrath; P G Matthews; C I Johnston
Journal:  Clin Exp Pharmacol Physiol       Date:  1980 Sep-Oct       Impact factor: 2.557

10.  Captopril in clinical hypertension. Changes in components of renin-angiotensin system and in body composition in relation to fall in blood pressure with a note on measurement of angiotensin II during converting enzyme inhibition.

Authors:  A B Atkinson; J J Morton; J J Brown; D L Davies; R Fraser; P Kelly; B Leckie; A F Lever; J I Robertson
Journal:  Br Heart J       Date:  1980-09
View more
  45 in total

1.  Unexpected first dose hypotensive reaction to enalapril.

Authors:  P J Mullen
Journal:  Postgrad Med J       Date:  1990-12       Impact factor: 2.401

2.  'First dose' hypotension and venodilatation.

Authors:  S Capewell; A Capewell
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

Review 3.  Allopathy--the therapeutic legacy.

Authors:  G D Johnston
Journal:  Ir J Med Sci       Date:  1989-01       Impact factor: 1.568

4.  The captopril test: an aid to investigation of hypertension.

Authors:  C E Daman Willems; V Shah; M Uchiyama; M J Dillon
Journal:  Arch Dis Child       Date:  1989-02       Impact factor: 3.791

5.  The effect of perindopril and hydrochlorothiazide alone and in combination on blood pressure and on the renin-angiotensin system in hypertensive subjects.

Authors:  C L Brown; C I Backhouse; J C Grippat; J P Santoni
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 6.  Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

Review 7.  Medicine in the elderly.

Authors:  P Diggory; A Homer; J Liddle; C F Pratt; S Samadian; R Tozer; C Weinstein
Journal:  Postgrad Med J       Date:  1991-05       Impact factor: 2.401

8.  Start of therapy with the angiotensin II antagonist losartan after immediate switch from pretreatment with an ACE inhibitor.

Authors:  J Scholze; M Stapff
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

9.  The effects of age on the pharmacokinetics and pharmacodynamics of single oral doses of benazepril and enalapril.

Authors:  N J Macdonald; A Sioufi; C A Howie; J R Wade; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1993-09       Impact factor: 4.335

Review 10.  Enalapril in hypertension and congestive heart failure. Overall review of efficacy and safety.

Authors:  F Moncloa; J A Sromovsky; J F Walker; R O Davies
Journal:  Drugs       Date:  1985       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.